Clinical Neurology and Neurosurgery
Volume 111, Issue 3 , Pages 270-273 , April 2009

Aspirin resistance determined with PFA-100 does not predict new thrombotic events in patients with stable ischemic cerebrovascular disease

  • Giorgio B. Boncoraglio

      Affiliations

    • Cerebrovascular Diseases Unit, Fondazione IRCCS Istituto Neurologico “Carlo Besta”, Via Celoria 11, 20133 Milano, Italy
    • Corresponding Author InformationCorresponding author. Tel.: +39 02 2394 2385; fax: +39 02 70638217.
    • ,
  • Antonella Bodini

      Affiliations

    • Consiglio Nazionale delle Ricerche, Istituto di Matematica Applicata e Tecnologie Informatiche, Milano, Italy
    • ,
  • Carla Brambilla

      Affiliations

    • Consiglio Nazionale delle Ricerche, Istituto di Matematica Applicata e Tecnologie Informatiche, Milano, Italy
    • ,
  • Elena Corsini

      Affiliations

    • Laboratory of Clinical Investigations, Fondazione IRCCS Istituto Neurologico “Carlo Besta”, Milano, Italy
    • ,
  • Maria R. Carriero

      Affiliations

    • Cerebrovascular Diseases Unit, Fondazione IRCCS Istituto Neurologico “Carlo Besta”, Via Celoria 11, 20133 Milano, Italy
    • ,
  • Eugenio A. Parati

      Affiliations

    • Cerebrovascular Diseases Unit, Fondazione IRCCS Istituto Neurologico “Carlo Besta”, Via Celoria 11, 20133 Milano, Italy

Received 28 April 2008 ,Revised 6 September 2008 ,Accepted 2 November 2008.

References 

  1. Patrono C, Garcia Rodriguez LA, Landolfi R, Baigent C. Low-dose aspirin for the prevention of atherothrombosis. N Engl J Med. 2005;353:2373–2383
  2. Antithrombotic Trialists’ Collaboration . Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002;324:71–86
  3. Patrono C, Coller B, FitzGerald GA, Hirsh J, Roth G. Platelet-active drugs: the relationships among dose, effectiveness, and side effects: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004;126:234S–264S
  4. Eikelboom JW, Hankey GJ. Failure of aspirin to prevent atherothrombosis: potential mechanisms and implications for clinical practice. Am J Cardiovasc Drugs. 2004;4:57–67
  5. Hankey GJ, Eikelboom JW. Aspirin resistance. Lancet. 2006;367:606–617
  6. Krasopoulos G, Brister SJ, Beattie WS, Buchanan MR. Aspirin “resistance” and risk of cardiovascular morbidity: systematic review and meta-analysis. BMJ. 2008;336:195–198
  7. Szczeklik A, Musial J, Undas A, Sanak M. Aspirin resistance. J Thromb Haemost. 2005;3:1655–1662
  8. Mason PJ, Jacobs AK, Freedman JE. Aspirin resistance and atherothrombotic disease. J Am Coll Cardiol. 2005;46:986–993
  9. Eikelboom JW, Hirsh J, Weitz JI, Johnston M, Yi Q, Yusuf S. Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. Circulation. 2002;105:1650–1655
  10. Sanderson S, Emery J, Baglin T, Kinmonth AL. Narrative review: aspirin resistance and its clinical implications. Ann Intern Med. 2005;142:370–380
  11. Hennekens CH, Schror K, Weisman S, FitzGerald GA. Terms and conditions: semantic complexity and aspirin resistance. Circulation. 2004;110:1706–1708
  12. Patrono C, Rocca B. Aspirin: promise and resistance in the new millennium. Arterioscler Thromb Vasc Biol. 2008;28:s25–32
  13. Michelson AD, Cattaneo M, Eikelboom JW, Gurbel P, Kottke-Marchant K, Kunicki TJ, et al. Platelet Physiology Subcommittee of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis; Working Group on Aspirin Resistance: Aspirin resistance: position paper of the Working Group on Aspirin Resistance. J Thromb Haemost. 2005;3:1309–1311
  14. Campbell CL, Steinhubl SR. Variability in response to aspirin: do we understand the clinical relevance?. J Thromb Haemost. 2005;3:665–669
  15. Jilma B. Platelet function analyzer (PFA-100): a tool to quantify congenital or acquired platelet dysfunction. J Lab Clin Med. 2001;138:152–163
  16. Favaloro EJ. Clinical application of the PFA-100. Curr Opin Hematol. 2002;9:407–415
  17. Reny JL, De Moerloose P, Dauzat M, Fontana P. Use of the PFA-100 closure time to predict cardiovascular events in aspirin-treated cardiovascular patients: a systematic review and meta-analysis. J Thromb Haemost. 2008;6:444–450
  18. Hack W, Kaste M, Bogousslavsky J, Brainin M, Chamorro A, Lees K, et al. European Stroke Initiative Executive Committee and the EUSI Writing Committee: European Stroke Initiative Recommendations for Stroke Management-update 2003. Cerebrovasc Dis. 2003;16:311–337
  19. Kuller LH, Longstreth WT, Arnold AM, Bernick C, Bryan RN, Beauchamp NJ. Cardiovascular Health Study Collaborative Research Group: White matter hyperintensity on cranial magnetic resonance imaging: a predictor of stroke. Stroke. 2004;35:1821–1825
  20. Adams HP, Bendixen BH, Kappelle LJ, Biller J, Love BB, Gordon DL, et al. Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. Stroke. 1993;24:35–41
  21. Alberts MJ, Bergman DL, Molner E, Jovanovic BD, Ushiwata I, Teruya J. Antiplatelet effect of aspirin in patients with cerebrovascular disease. Stroke. 2004;35:175–178
  22. McCabe DJ, Harrison P, Mackie IJ, Sidhu PS, Lawrie AS, Purdy G, et al. Assessment of the antiplatelet effects of low to medium dose aspirin in the early and late phases after ischaemic stroke and TIA. Platelets. 2005;16:269–280
  23. Grundmann K, Jaschonek K, Kleine B, Dichgans J, Topka H. Aspirin non-responder status in patients with recurrent cerebral ischemic attacks. J Neurol. 2003;250:63–66
  24. Harrison P, Segal H, Blasbery K, Furtado C, Silver L, Rothwell PM. Screening for aspirin responsiveness after transient ischemic attack and stroke: comparison of 2 point-of-care platelet function tests with optical aggregometry. Stroke. 2005;36:1001–1005
  25. Christiaens L, Ragot S, Mergy J, Allal J, Macchi L. Major clinical vascular events and aspirin-resistance status as determined by the PFA-100 method among patients with stable coronary artery disease: a prospective study. Blood Coagul Fibrinolysis. 2008;19:235–239
  26. Andersen K, Hurlen M, Arnesen H, Seljeflot I. Aspirin non-responsiveness as measured by PFA-100 in patients with coronary artery disease. Thromb Res. 2002;108:37–42
  27. Gum PA, Kottke-Marchant K, Welsh PA, White J, Topol EJ. A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. J Am Coll Cardiol. 2003;41:961–965
  28. Gianetti J, Parri MS, Sbrana S, Paoli F, Maffei S, Paradossi U, et al. Platelet activation predicts recurrent ischemic events after percutaneous coronary angioplasty: a 6 months prospective study. Thromb Res. 2006;118:487–493
  29. Marcucci R, Paniccia R, Antonucci E, Gori AM, Fedi S, Giglioli C, et al. Usefulness of aspirin resistance after percutaneous coronary intervention for acute myocardial infarction in predicting one-year major adverse coronary events. Am J Cardiol. 2006;98:1156–1159
  30. Pamukcu B, Oflaz H, Oncul A, Umman B, Mercanoglu F, Ozcan M, et al. The role of aspirin resistance on outcome in patients with acute coronary syndrome and the effect of clopidogrel therapy in the prevention of major cardiovascular events. J Thromb Thrombolysis. 2006;22:103–110
  31. Atiemo AD, Ng’alla LS, Vaidya D, Williams MS. Abnormal PFA-100 closure time is associated with increased platelet aggregation in patients presenting with chest pain. J Thromb Thrombolysis. 2008;25:173–178
  32. Hobikoglu GF, Norgaz T, Aksu H, Ozer O, Erturk M, Destegul E, et al. The effect of acetylsalicylic acid resistance on prognosis of patients who have developed acute coronary syndrome during acetylsalicylic acid therapy. Can J Cardiol. 2007;23:201–206
  33. Pamukcu B, Oflaz H, Onur I, Oncul A, Ozcan M, Umman B, et al. Clinical relevance of aspirin resistance in patients with stable coronary artery disease: a prospective follow-up study (PROSPECTAR). Blood Coagul Fibrinolysis. 2007;18:187–192
  34. Grotemeyer KH, Scharafinski HW, Husstedt IW. Two-year follow-up of aspirin responder and aspirin non responder. A pilot-study including 180 post-stroke patients. Thromb Res. 1993;71:397–403
  35. Seok JI, Joo IS, Yoon JH, Choi YJ, Lee PH, Huh K, et al. Can aspirin resistance be clinically predicted in stroke patients?. Clin Neurol Neurosurg. 2008;110:110–116

PII: S0303-8467(08)00390-9

doi: 10.1016/j.clineuro.2008.11.001

Clinical Neurology and Neurosurgery
Volume 111, Issue 3 , Pages 270-273 , April 2009

Article Tools

* Image Usage & Resolution